Related Experiment Video
Updated: Nov 5, 2025
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
A Multicenter Pilot Randomized Clinical Trial of a Home-Based Exercise Program for Patients With Cirrhosis: The
Jennifer C Lai1, Jennifer L Dodge, Matthew R Kappus
11Department of Medicine, University of California-San Francisco, San Francisco, California, USA; 2Division of Gastroenterology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; 3Department of Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland, USA; 4Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
The STRIVE home exercise program for cirrhosis patients was safe but had low adherence. While physical function showed minimal improvement, quality of life significantly increased in patients completing the strength training intervention.
Area of Science:
- Hepatology
- Exercise Physiology
- Clinical Trials
Background:
- Cirrhosis significantly impairs physical function and quality of life.
- Home-based exercise interventions are needed to manage physical decline in cirrhosis patients.
Purpose of the Study:
- To evaluate the safety and efficacy of the STRIVE (Strength Training Intervention) program.
- To assess the impact of a home-based strength training program on physical function and quality of life in cirrhosis patients.
Main Methods:
- A pilot randomized controlled trial involving adult patients with cirrhosis.
- Participants were randomized to 12 weeks of the STRIVE program (strength training video + health coach) or standard of care (SOC).
- Physical function was measured by the Liver Frailty Index (LFI); quality of life by the Chronic Liver Disease Questionnaire (CLDQ).
Main Results:
- STRIVE was safely administered, with no reported adverse events.
- No significant difference in LFI change was observed between STRIVE and SOC groups (P = 0.65).
- STRIVE participants showed a trend towards improved CLDQ scores compared to SOC (P = 0.09), with adherence at 14%.
Conclusions:
- The STRIVE program is safe for cirrhosis patients but demonstrated low adherence.
- While not significantly improving physical function (LFI), STRIVE was associated with substantial improvements in quality of life (CLDQ).
